Bevacizumab

Key Messages

• The Formulary Management Expert Committee (FMEC) recommends that bevacizumab in combination with chemotherapy not be reimbursed in the second or later line of therapy for patients with recurrent or metastatic endometrial cancer.
• FMEC reviewed 1 trial of bevacizumab plus chemotherapy compared to chemotherapy alone, and a cost comparison of bevacizumab versus other treatments used in Canada. The clinical evidence reviewed demonstrates that bevacizumab has no added benefit compared to standard chemotherapy on overall survival (OS) and progression-free survival (PFS). A higher proportion of patients experienced severe adverse events or discontinued treatment due to adverse events with bevacizumab plus chemotherapy.
• Patients and clinicians identified a need for therapies that improve survival, maintain health-related quality of life (HRQoL), and are less toxic than current options in second or later lines of therapy for endometrial cancer. FMEC concluded that bevacizumab in combination with chemotherapy does not demonstrate acceptable clinical value or fill unmet clinical or nonclinical needs identified by patients and clinicians.